Browse News
Filter News
Found 9,577 articles
-
Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
9/27/2023
Gracell Biotechnologies Inc. today presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate.
-
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
9/27/2023
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG").
-
Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
9/27/2023
Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced that the first patients have been dosed in its ReSET-02 Phase I/II trial for adult acute leukemia and myelodysplasia syndrome patients.
-
TC BioPharm to Present at the LD Micro Main Event XVI
9/27/2023
TC BioPharm today announced that CEO, Bryan Kobel will present at the LD Micro 16th annual Main Event conference taking place on October 3-5, 2023.
-
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
9/27/2023
Coeptis Therapeutics Holdings, Inc. today announced that Colleen Delaney, MD, MSc, Chief Scientific and Medical Officer, will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.
-
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
9/27/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.
-
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
9/27/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.
-
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
9/27/2023
Adicet Bio, Inc. (Nasdaq: ACET) today announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023.
-
Keep up with the regulator's latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
9/26/2023
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced that the first patient has been dosed in a Phase 1b/2 clinical trial evaluating its lead candidate, GC012F, in patients with relapsed or refractory multiple myeloma (RRMM) in the United States. GC012F is the Company’s autologous therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, developed on the proprietary FasTCAR next-day manufacturing platform.
-
Kyverna Therapeutics and ElevateBio to Advance Kyverna's Ingenui-T Cell Therapy Manufacturing
9/26/2023
Kyverna Therapeutics ("Kyverna") and ElevateBio, LLC ("ElevateBio") today announced a partnership to advance process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies.
-
Capstan Therapeutics to Participate in Upcoming Industry Conferences
9/26/2023
Capstan Therapeutics, Inc. today announced that Capstan management will participate in the following upcoming industry conferences.
-
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
9/25/2023
Genmab A/S announced that the European Commission has granted conditional marketing authorization for TEPKINLY® as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
-
Celyad Oncology announces the termination of its American Depository Receipt program
9/25/2023
Celyad Oncology SA announces that Citibank, N.A., as depositary, shall issue the notice of terminating its American Depository Receipt program of American Depositary Shares representing ordinary shares to the holders of ADSs according to the requirements under the deposit agreement.
-
HoneyNaps Receives U.S. FDA Approval for Groundbreaking AI Sleep Disorder Diagnosis Software
9/25/2023
HoneyNaps, the leading-edge AI-based sleep disorder diagnosis software company, has announced that its SOMNUM AI sleep disease analysis algorithm has been approved by the U.S. Food and Drug Administration (FDA).
-
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
9/25/2023
Genmab A/S announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, after two or more lines of systemic therapy.
-
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
9/25/2023
CytoMed Therapeutics Limited today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).
-
Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology
9/25/2023
Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes with chimeric antigen receptor technology developed by the Max Delbrück Center.